UroGen Pharma (URGN) just had a clear catalyst. The FDA accepted its New Drug Application for UGN-103, an investigational bladder cancer treatment, and set a Prescription Drug User Fee Act decision date of June 14, 2027.
UroGen Pharma’s share price tells a mixed story. The stock has pulled back sharply in the short term, with the share price down 21.0% over 30 days and 22.0% over 90 days, yet year to date it is still up 50.4% and the 1-year total shareholder return is 89.8%. Over three years, the total shareholder return has risen to just over 2x, which points to strong longer term momentum even as traders reassess risk around drug development milestones such as the UGN-103 filing.
Scan other cancer-focused opportunities moving on clinical trial and FDA milestones with our hand-selected 33 healthcare AI stocks alongside UroGen Pharma in your research pipeline.
UroGen Pharma now appears to be a stronger bladder cancer platform story than it did a few months ago, even after the pullback. The key question is straightforward: are you paying a fair price for that progress today?
Most Popular Narrative: 43% Undervalued
Analysts following UroGen Pharma see a big gap between where the shares trade today at $34.15 and their blended fair value view of $60, which anchors their story on Zusduri momentum and a broader urothelial cancer platform.
Launch of ZUSDURI in a large, underserved market with a $5 billion annual opportunity is supported by demographic trends, particularly an aging population with rising incidence of urological cancers, positioning UroGen for substantial revenue growth as adoption expands beyond early adopters and reimbursement hurdles are resolved.
See why 15 investors see UroGen Pharma as 43% undervalued.
Result: Fair Value of $60 (UNDERVALUED)
Still, the story around UroGen Pharma can break if heavy operating losses continue at current levels and if reimbursement or J-code timing slows Zusduri uptake.
Find out about the key risks to this UroGen Pharma narrative.
Next Steps
Mixed signals around UroGen Pharma can make the story feel murky. Act promptly, review the data independently, and weigh both the potential upside and downside through the 3 key rewards and 3 important warning signs
Looking for more UroGen Pharma sized ideas?
Do not stop with UroGen Pharma. Broaden your watchlist using focused screeners that surface clear, data backed ideas you might otherwise miss completely.
- Target potential mispricings by scanning a curated set of quality companies that screens for fundamentals with the 35 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by reviewing a list of solid balance sheet and fundamentals (25 results) that can better handle pressure when conditions get tough.
- Get ahead of the crowd by checking a focused pool of 20 high quality undiscovered gems before attention pushes them onto everyone else's radar.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com